Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13392653 | 1.00 | ESR1 (0.39) | ESR1CYP19A1CHRM2CHRM4CHRM1 | |
| SCHEMBL13392644 | 1.00 | ESR1 (0.39) | ESR1CYP19A1CHRM2CHRM4CHRM1 | |
| SCHEMBL4188211 | 1.00 | ESR1 (0.39) | ESR1CYP19A1CHRM2CHRM4CHRM1 | |
| SCHEMBL13853950 | 0.87 | CHRM2 (0.37) | CYP19A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13392652 | 0.82 | CYP19A1 (0.34) | CYP19A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL20110152 | 0.77 | ESR1 (0.38) | ESR1 | |
| SCHEMBL15045301 | 0.76 | ESR1 (0.41) | ESR1CYP19A1 | |
| SCHEMBL13392638 | 0.76 | CYP19A1 (0.40) | CYP19A1ALDH1A1TP53MAPTMAPK1 | |
| SCHEMBL8575567 | 0.76 | CYP19A1 (0.40) | CYP19A1ALDH1A1TP53MAPTMAPK1 | |
| SCHEMBL7104580 | 0.76 | CYP19A1 (0.40) | CYP19A1ALDH1A1TP53MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20100009949-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-01-14 | — | — | US | disclosed |
| US-20100009949-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-01-14 | — | — | US | disclosed |
| US-20090137828-A1 | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol | BIOXELL S.P.A. (IT) | 2009-05-28 | — | — | US | disclosed |
| US-20090137828-A1 | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol | BIOXELL S.P.A. (IT) | 2009-05-28 | — | — | US | disclosed |
| WO-2008043857-A2 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL SPA (IT) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008034908-A2 | USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS | BIOXELL SPA (IT) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007110109-A1 | NOVEL METHOD | BIOXELL SPA (IT) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007022433-A2 | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | BIOXELL S.P.A. (IT) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | CYP27B1, CYP2R1, SHBG | ESR1 3036/4885CYP19A1 25/4885CHRM2 2878/4885 |
| US-20090137828-A1 | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol | CYP24A1, CYP2R1, CYP27B1 | ESR1 352/4885CYP19A1 31/4885CHRM2 4223/4885 |
| US-20100009949-A1 | NOVEL METHOD | CYP24A1, CYP2R1, CYP27B1 | ESR1 382/4885CYP19A1 45/4885CHRM2 3267/4885 |
| US-20100093675-A1 | NOVEL METHOD | GC, VDR, CYP24A1 | ESR1 4365/4885CYP19A1 2283/4885CHRM2 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.